Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank65
3Y CAGR-41.9%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
-41.9%/yr
Quarterly compound
Percentile
P65
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.03% |
| Q3 2025 | 17.03% |
| Q2 2025 | -15.42% |
| Q1 2025 | 4.37% |
| Q4 2024 | 48.36% |
| Q3 2024 | -0.01% |
| Q2 2024 | 38.80% |
| Q1 2024 | -2610.95% |
| Q4 2023 | -77.36% |
| Q3 2023 | -5.35% |
| Q2 2023 | 1303.31% |
| Q1 2023 | 103.68% |
| Q4 2022 | 20.56% |
| Q3 2022 | 0.58% |
| Q2 2022 | -13.00% |
| Q1 2022 | -68.81% |
| Q4 2021 | -22.48% |
| Q3 2021 | -5.57% |
| Q2 2021 | -50.95% |
| Q1 2021 | -69.03% |
| Q4 2020 | 0.00% |